IRB #

STUDY00020229

Title

[NCI CIRB] A031702 - A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

Principal Investigator

Christopher Ryan

Study Purpose

This study is being done to test the good and bad effects of the drugs called cabozantinib, nivolumab and ipilimumab, when given in combination for advanced rare genitourinary cancer.

Medical Condition(s)

small cell carcinoma of the bladder
adenocarcinoma of the bladder
squamous cell carcinoma of the bladder
plasmacytoid urothelial carcinoma
penile cancer
sarcomatoid renal cell carcinoma
sarcomatoid urothelial carcinoma
renal medullary carcinoma
other miscellaneous histologic variants of the urothelial carcinoma
small cell neuroendocrine prostate cancer
testicular Sertoli or Leydig cell tumors
papillary and chromophobe renal cell carcinoma

Eligibility Criteria

- Participants must have one of the rare variants of stage IV (metastatic) genitourinary cancer listed in the conditions studied
- Participants must not have active brain metastases

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

Participants will be on study for up to 5 years from the time of study entry through follow up.

Minors Included

No

Contact

Knight Information Line - trials@ohsu.edu or 503-494-1080

Sponsor

Alliance

Recruitment End

07/03/2028

Compensation Provided

No


Go Back